The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tuberculosis Therapeutics Market Research Report 2025
Synopsis
Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis.
The global Tuberculosis Therapeutics market was valued at US$ 840.1 million in 2023 and is anticipated to reach US$ 1061 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tuberculosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis Therapeutics.
Report Scope
The Tuberculosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tuberculosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tuberculosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Aventis Pharmaceuticals
Sanofi -Aventis
Versapharma Incorporated
Sigma Pharmaceutical Pty
Novartis AG
Hoffmann-La Roche
Bayer Health Care
Segment by Type
Isoniazid
Rifampin
Pyrazinamide
Hydrazine Derivatives
Miscellaneous Anti-Tubercular Drugs
Ethambutol
Others
Segment by Application
Hospital
Pharmacy
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis.
The global Tuberculosis Therapeutics market was valued at US$ 840.1 million in 2023 and is anticipated to reach US$ 1061 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tuberculosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis Therapeutics.
Report Scope
The Tuberculosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tuberculosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tuberculosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Aventis Pharmaceuticals
Sanofi -Aventis
Versapharma Incorporated
Sigma Pharmaceutical Pty
Novartis AG
Hoffmann-La Roche
Bayer Health Care
Segment by Type
Isoniazid
Rifampin
Pyrazinamide
Hydrazine Derivatives
Miscellaneous Anti-Tubercular Drugs
Ethambutol
Others
Segment by Application
Hospital
Pharmacy
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tuberculosis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Isoniazid
1.2.3 Rifampin
1.2.4 Pyrazinamide
1.2.5 Hydrazine Derivatives
1.2.6 Miscellaneous Anti-Tubercular Drugs
1.2.7 Ethambutol
1.2.8 Others
1.3 Market by Application
1.3.1 Global Tuberculosis Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tuberculosis Therapeutics Market Perspective (2019-2030)
2.2 Tuberculosis Therapeutics Growth Trends by Region
2.2.1 Global Tuberculosis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tuberculosis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Tuberculosis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Tuberculosis Therapeutics Market Dynamics
2.3.1 Tuberculosis Therapeutics Industry Trends
2.3.2 Tuberculosis Therapeutics Market Drivers
2.3.3 Tuberculosis Therapeutics Market Challenges
2.3.4 Tuberculosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tuberculosis Therapeutics Players by Revenue
3.1.1 Global Top Tuberculosis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Tuberculosis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Tuberculosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tuberculosis Therapeutics Revenue
3.4 Global Tuberculosis Therapeutics Market Concentration Ratio
3.4.1 Global Tuberculosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tuberculosis Therapeutics Revenue in 2023
3.5 Tuberculosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Tuberculosis Therapeutics Product Solution and Service
3.7 Date of Enter into Tuberculosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tuberculosis Therapeutics Breakdown Data by Type
4.1 Global Tuberculosis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Tuberculosis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Tuberculosis Therapeutics Breakdown Data by Application
5.1 Global Tuberculosis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Tuberculosis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Tuberculosis Therapeutics Market Size (2019-2030)
6.2 North America Tuberculosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tuberculosis Therapeutics Market Size by Country (2019-2024)
6.4 North America Tuberculosis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tuberculosis Therapeutics Market Size (2019-2030)
7.2 Europe Tuberculosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tuberculosis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Tuberculosis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tuberculosis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Tuberculosis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tuberculosis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Tuberculosis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tuberculosis Therapeutics Market Size (2019-2030)
9.2 Latin America Tuberculosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tuberculosis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Tuberculosis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tuberculosis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Tuberculosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tuberculosis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Tuberculosis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aventis Pharmaceuticals
11.1.1 Aventis Pharmaceuticals Company Detail
11.1.2 Aventis Pharmaceuticals Business Overview
11.1.3 Aventis Pharmaceuticals Tuberculosis Therapeutics Introduction
11.1.4 Aventis Pharmaceuticals Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.1.5 Aventis Pharmaceuticals Recent Development
11.2 Sanofi -Aventis
11.2.1 Sanofi -Aventis Company Detail
11.2.2 Sanofi -Aventis Business Overview
11.2.3 Sanofi -Aventis Tuberculosis Therapeutics Introduction
11.2.4 Sanofi -Aventis Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.2.5 Sanofi -Aventis Recent Development
11.3 Versapharma Incorporated
11.3.1 Versapharma Incorporated Company Detail
11.3.2 Versapharma Incorporated Business Overview
11.3.3 Versapharma Incorporated Tuberculosis Therapeutics Introduction
11.3.4 Versapharma Incorporated Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.3.5 Versapharma Incorporated Recent Development
11.4 Sigma Pharmaceutical Pty
11.4.1 Sigma Pharmaceutical Pty Company Detail
11.4.2 Sigma Pharmaceutical Pty Business Overview
11.4.3 Sigma Pharmaceutical Pty Tuberculosis Therapeutics Introduction
11.4.4 Sigma Pharmaceutical Pty Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.4.5 Sigma Pharmaceutical Pty Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Tuberculosis Therapeutics Introduction
11.5.4 Novartis AG Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.5.5 Novartis AG Recent Development
11.6 Hoffmann-La Roche
11.6.1 Hoffmann-La Roche Company Detail
11.6.2 Hoffmann-La Roche Business Overview
11.6.3 Hoffmann-La Roche Tuberculosis Therapeutics Introduction
11.6.4 Hoffmann-La Roche Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.6.5 Hoffmann-La Roche Recent Development
11.7 Bayer Health Care
11.7.1 Bayer Health Care Company Detail
11.7.2 Bayer Health Care Business Overview
11.7.3 Bayer Health Care Tuberculosis Therapeutics Introduction
11.7.4 Bayer Health Care Revenue in Tuberculosis Therapeutics Business (2019-2024)
11.7.5 Bayer Health Care Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
